GAITHERSBURG, Md., March 30, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today reported financial results for the three and 12 months ended December 31, 2010.
